CN1169612C - Adsorbent based on montmorillonite for purifying blood and its preparing method - Google Patents
Adsorbent based on montmorillonite for purifying blood and its preparing method Download PDFInfo
- Publication number
- CN1169612C CN1169612C CNB031150179A CN03115017A CN1169612C CN 1169612 C CN1169612 C CN 1169612C CN B031150179 A CNB031150179 A CN B031150179A CN 03115017 A CN03115017 A CN 03115017A CN 1169612 C CN1169612 C CN 1169612C
- Authority
- CN
- China
- Prior art keywords
- montmorillonite
- blood
- preparation
- agent based
- adsorbing agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229910052901 montmorillonite Inorganic materials 0.000 title claims abstract description 62
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 title claims abstract description 33
- 239000008280 blood Substances 0.000 title abstract description 17
- 210000004369 blood Anatomy 0.000 title abstract description 17
- 239000003463 adsorbent Substances 0.000 title abstract description 11
- 238000000034 method Methods 0.000 title description 2
- 108010010803 Gelatin Proteins 0.000 claims abstract description 20
- 239000008273 gelatin Substances 0.000 claims abstract description 20
- 229920000159 gelatin Polymers 0.000 claims abstract description 20
- 235000019322 gelatine Nutrition 0.000 claims abstract description 20
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 20
- 239000000725 suspension Substances 0.000 claims abstract description 17
- 238000002360 preparation method Methods 0.000 claims abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000007788 liquid Substances 0.000 claims abstract description 7
- 239000003094 microcapsule Substances 0.000 claims abstract description 4
- 238000003756 stirring Methods 0.000 claims description 30
- 239000000243 solution Substances 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 229920001817 Agar Polymers 0.000 claims description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 239000008272 agar Substances 0.000 claims description 9
- 230000001954 sterilising effect Effects 0.000 claims description 9
- 238000004659 sterilization and disinfection Methods 0.000 claims description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 8
- 229920000936 Agarose Polymers 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 239000012153 distilled water Substances 0.000 claims description 6
- 239000012467 final product Substances 0.000 claims description 6
- 238000012856 packing Methods 0.000 claims description 6
- 230000018044 dehydration Effects 0.000 claims description 5
- 238000006297 dehydration reaction Methods 0.000 claims description 5
- 238000005342 ion exchange Methods 0.000 claims description 5
- 238000007711 solidification Methods 0.000 claims description 5
- 230000008023 solidification Effects 0.000 claims description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 claims description 4
- 159000000000 sodium salts Chemical class 0.000 claims description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 4
- 235000011152 sodium sulphate Nutrition 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- CEYULKASIQJZGP-UHFFFAOYSA-L disodium;2-(carboxymethyl)-2-hydroxybutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O CEYULKASIQJZGP-UHFFFAOYSA-L 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 239000004317 sodium nitrate Substances 0.000 claims description 2
- 235000010344 sodium nitrate Nutrition 0.000 claims description 2
- 239000001488 sodium phosphate Substances 0.000 claims description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 2
- 239000007790 solid phase Substances 0.000 claims description 2
- 239000013638 trimer Substances 0.000 claims description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 239000000463 material Substances 0.000 abstract description 8
- 238000001179 sorption measurement Methods 0.000 abstract description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract description 5
- 229910052799 carbon Inorganic materials 0.000 abstract description 5
- 238000005516 engineering process Methods 0.000 abstract description 4
- 229910001415 sodium ion Inorganic materials 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 3
- 125000000129 anionic group Chemical group 0.000 abstract description 2
- 125000002091 cationic group Chemical group 0.000 abstract description 2
- 230000001951 hemoperfusion Effects 0.000 abstract description 2
- 230000015271 coagulation Effects 0.000 abstract 3
- 238000005345 coagulation Methods 0.000 abstract 3
- 229920001661 Chitosan Polymers 0.000 abstract 2
- 231100000167 toxic agent Toxicity 0.000 abstract 2
- 239000003440 toxic substance Substances 0.000 abstract 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 230000007935 neutral effect Effects 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 238000000746 purification Methods 0.000 description 6
- 238000005303 weighing Methods 0.000 description 5
- 238000013019 agitation Methods 0.000 description 4
- 230000008081 blood perfusion Effects 0.000 description 4
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical group [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000007096 poisonous effect Effects 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 208000007788 Acute Liver Failure Diseases 0.000 description 1
- 206010000804 Acute hepatic failure Diseases 0.000 description 1
- 208000010334 End Stage Liver Disease Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 201000002015 Thyroid Crisis Diseases 0.000 description 1
- 206010043786 Thyrotoxic crisis Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 239000002156 adsorbate Substances 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000003889 chemical engineering Methods 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000011444 chronic liver failure Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 239000002734 clay mineral Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- ONCZQWJXONKSMM-UHFFFAOYSA-N dialuminum;disodium;oxygen(2-);silicon(4+);hydrate Chemical compound O.[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[Na+].[Na+].[Al+3].[Al+3].[Si+4].[Si+4].[Si+4].[Si+4] ONCZQWJXONKSMM-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 229940080314 sodium bentonite Drugs 0.000 description 1
- 229910000280 sodium bentonite Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019832 sodium triphosphate Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Landscapes
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Silicates, Zeolites, And Molecular Sieves (AREA)
Abstract
The present invention discloses a blood purifying adsorbent based on montmorillonite and a preparation method thereof. The blood purifying adsorbent based on montmorillonite is a montmorillonite microcapsule of which the chitosan types and the gelatin types are packed and embedded. The blood purifying adsorbent has the preparation method that separated and purified sodium base montmorillonite or other montmorillonite exchanged by sodium ions are mixed with a chitosan and gelatin type solution to be manufactured into a suspension which is pressurized to be sprayed in cold coagulation liquid, and the suspension and the cold coagulation liquid are centrifugated or filtered and separated, washed by water, disinfected, baked and packed after being stirred for coagulation. The adsorption capacity of the adsorbent on cationic toxicants is higher than that of the existing hemoperfusion adsorption material of spheric active carbon, and the adsorption capacity of the adsorbent on anionic and electrically neutral toxicants is approximately equivalent to that of the spheric active carbon. The blood purifying adsorbent has the advantages of favorable biological compatibility, good blood compatibility, safe operation, wide raw material sources, low cost, simple preparation technology and less required investment.
Description
Technical field
The present invention relates to a kind of blood-purifying adsorbing agent and preparation method thereof.
Background technology
Blood purification therapy (Blood Purification) is along with bio-medical engineering material and cellular elements biology and industrial expansion thereof and the new technology that fast development is got up, blood perfusion (Hemoperfusion as one of blood purification important component part, HP) indication is extensive, cost is lower, can promote the disease recovery from illness rapidly, save patient's life.Improvement along with adsorbent kind and performance, clinical practice is extensive day by day, by generally being used for handling anxious, severe medicine toxic poisoning, develop into treatment acute and chronic liver failure (artificial liver), acute or chronic renal failure (artificial kidney), thyroid crisis, schizophrenia, systemic loupus erythematosus, psoriasis, septicopyemia etc.
Blood perfusion is the important component part of biomedical engineering, be between medical science, material science and chemical engineering science, to have intercrossing, a marginal subject, its precise meaning is blood absorption, promptly by extracorporal circulatory system, by adsorbent units (perfusion device) with wide spectrum adsorpting detoxication effect or ligands specific, remove endogenous or exogenous morbid substance (adsorbate) in the blood, regulate the stable of the interior microenvironment of body, reach the purpose of alleviating clinical symptoms, cure diseases, the reduction death rate.Adsorbent commonly used at present mainly is active carbon and various resin, exist in varying degrees that adsorptive selectivity is bad, blood compatibility is poor, problem such as Hemodynamics instability in the adsorption process, can not satisfy the clinical demand of blood perfusion far away, research and development are efficient, high selectivity, can realize that the miniaturization of perfusion device, differential adsorbent are the important topics in blood purification field.
Summary of the invention
The purpose of this invention is to provide a kind of blood-purifying adsorbing agent based on montmorillonite and preparation method thereof.
Blood-purifying adsorbing agent based on montmorillonite of the present invention is a kind of montmorillonite micro-capsule with shitosan and the embedding of gelatin class bag.
Its preparation method comprises the steps:
1) with distilled water shitosan being configured to concentration is 1~8% the aqueous solution, adds and the equiponderant gelatin class of shitosan again, stirs also heating, dissolves fully until solid phase;
2) the na-montmorillonite powder that weight is equivalent to solution weight 15~35% joins in the above-mentioned solution, stirs and makes suspension, then 30~60 ℃ of constant temperature 2~6 hours, and stirs frequently;
3) pressurization of above-mentioned suspension is sprayed in the cold solidification liquid, be stirred to it is solidified;
4) centrifugal or isolated by filtration, washing, sterilization, oven dry below 80 ℃, packing gets final product.
Among the present invention, said gelatin class is one or more in gelatin, agar and the agarose.Solidification liquid can be to be 0.1~5% solution with one or more concentration that are configured in sodium phosphate trimer, sodium sulphate, sodium carbonate, natrium citricum and the NaOH.The sterilization of final products should be heated to 110~120 ℃ in steam, and keeps 20~30 minutes.
Among the present invention, said na-montmorillonite powder can be natural na-montmorillonite powder, also can be that the montmorillonite of other type is made according to the following steps:
1) will be the sodium salt of montmorillonite 5~15% through separating the montmorillonite and the weight of purifying, and add water and stir, make the suspension ore pulp of concentration about 10%;
2) under 40~100 ℃ of temperature, ion-exchange reactions at least six hours, during stir frequently;
3) precipitation is removed the particle greater than 2 microns, and the upper strata suspension obtains na-montmorillonite behind centrifugal or filtering means dehydration, and water cleans for several times, and dehydration again;
4) gains are ground to less than 300 orders in oven dry below 80 ℃, obtain water content less than 10% na-montmorillonite powder.
Here, the used sodium salt of preparation na-montmorillonite can be sodium chloride, sodium nitrate, sodium sulphate.
Advantage of the present invention is:
1) raw materials used wide material sources and with low cost;
2) preparation technology is simple, required small investment;
3) montmorillonite is much higher than existing blood perfusion sorbing material spheric active carbon to the adsorption capacity of cationic poisonous substance, and is roughly suitable to the adsorption capacity and the spheric active carbon of anionic and electroneutral poisonous substance;
4) montmorillonite, shitosan and gelatin class are biological affine material, have good blood compatibility, and be safe in utilization.
The specific embodiment
The raw material that the present invention uses is the natural na-montmorillonite of purifying through separating, and has another name called sodium bentonite.Or the montmorillonite of other type, through sodium ion exchange, the na-montmorillonite of making.The purification technique of montmorillonite is well-known, and it comprises that suspension is made in pulverizing, making beating, the steps such as particle less than 2 microns are collected in classification.This highly purified montmorillonite is the clay mineral of a kind of light green color, light yellow tool layered crystal structure.Separate purification process and can select conventional mining equiment for use.
Bag embedding material selection shitosan and gelatin class mainly are because they have good bioaffinity and blood compatibility, and in addition, these two kinds of materials all obtain easily, and with low cost.
Select na-montmorillonite for use, or the montmorillonite of other type carried out sodium ion ion-exchange, be because na-montmorillonite has higher molecular activity, it has stronger selective adsorption capacity to each cationoid in the blood, and the sodium ion that discharges does not have obvious influence to the electrolyte balance and the blood chemistry composition of human body after the reaction.
Na-montmorillonite can be selected the conventional drying method for use, and baking temperature should be above 80 ℃; Also can the natural drying drying at the dry climate environment, again it is ground to granularity and is not more than 300 orders.
When configuration shitosan and gelatin class solution, preferably adopt the water-bath heating, to accelerate dissolution velocity.
The concentration of na-montmorillonite in shitosan and gelatin class solution preferably is controlled at about 25%, and overrich then is difficult to carry out next step operation, crosses rare performance that then can influence final products.
The suspension of na-montmorillonite, shitosan and gelatin class is sprayed in the solidification liquid, can select spraying apparatus routinely for use.The size of montmorillonite micro-capsule can be regulated by atomisation pressure and shower nozzle micro-pore diameter.
The sterilization of final products recommends to use Steam Heating, the decomposition in order to avoid montmorillonite dewaters because of heating-up temperature is too high.
Following example will further specify the present invention.
Embodiment 1
1) takes by weighing 1Kg through separating the ca-montmorillonite of purifying, add 9 liters in water, stir and make suspension.Add 150g NaCl, the back that stirs (needing 20 minutes approximately) is heated to about 60 ℃, ion-exchange reactions six hours, during stir frequently.Centrifugation then, the supernatant liquor that inclines adds 9 liters in water again, stirs, and continues centrifugation, and supernatant liquor inclines.Repeat 3~4 times, dehydration again, 80 ℃ of temperature oven dry are ground to less than 300 orders, get the na-montmorillonite powder.
2) add shitosan and each 40g of gelatin in 1 liter of distilled water, heating and stirring in 60 ℃ of water-baths are until dissolving fully.
3) take by weighing 300g na-montmorillonite powder, join in shitosan and the gelatin solution, stir, and in 60 ℃ of water-baths constant temperature 3 hours, during stir frequently.
4) adding the concentration prepare in advance in container is 1% NaOH solution, when stirring, the suspension of na-montmorillonite, shitosan and gelatin is sprayed in the container.
5) continue gentle agitation after 20 minutes, centrifugal or isolated by filtration is washed to neutrality, moise-heat sterilization, and 80 ℃ of temperature oven dry, packing gets final product.
Embodiment 2
1) add shitosan and each 40g of agar in 1 liter of distilled water, heating and stirring in 50 ℃ of water-baths are until dissolving fully.
2) take by weighing the na-montmorillonite powder that 300g separate to purify, join in shitosan and the agar solution, stir, and in 50 ℃ of water-baths constant temperature 3 hours, during stir frequently.
3) adding the concentration prepare in advance in container is 1% sodium tripolyphosphate solution, when stirring, the suspension of na-montmorillonite, shitosan and agar is sprayed in the container.
4) continue gentle agitation after 20 minutes, centrifugal or isolated by filtration is washed to neutrality, moise-heat sterilization, and 80 ℃ of temperature oven dry, packing gets final product.
Embodiment 3
1) add shitosan and each 40g of agar in 1 liter of distilled water, heating and stirring in 50 ℃ of water-baths are until dissolving fully.
2) take by weighing the na-montmorillonite powder that 300g separate to purify, join in shitosan and the agarose solution, stir, and in 50 ℃ of water-baths constant temperature 3 hours, during stir frequently.
3) adding the concentration prepare in advance in container is 1.5% metabisulfite solution, when stirring, the suspension of na-montmorillonite, shitosan and agarose is sprayed in the container.
4) continue gentle agitation after 30 minutes, centrifugal or isolated by filtration is washed to neutrality, moise-heat sterilization, and 80 ℃ of temperature oven dry, packing gets final product.
Embodiment 4
1) add shitosan and each 30g of agar in 1 liter of distilled water, heating and stirring in 40 ℃ of water-baths are until dissolving fully.
2) take by weighing 250g na-montmorillonite powder, join in shitosan and the agar solution, stir, and in 40 ℃ of water-baths constant temperature 4 hours, during stir frequently.
3) adding the concentration prepare in advance in container is 1.5% sodium citrate solution, when stirring, the suspension of na-montmorillonite, shitosan and agarose is sprayed in the container.
4) continue gentle agitation after 30 minutes, centrifugal or isolated by filtration is washed to neutrality, moise-heat sterilization, and 80 ℃ of temperature oven dry, packing gets final product.
Claims (9)
1. blood-purifying adsorbing agent based on montmorillonite is characterized in that it is a montmorillonite micro-capsule with shitosan and the embedding of gelatin class bag.
2. the blood-purifying adsorbing agent based on montmorillonite according to claim 1 is characterized in that said gelatin class is one or more in gelatin, agar and the agarose.
3. the preparation method of the blood-purifying adsorbing agent based on montmorillonite according to claim 1 is characterized in that its step is as follows:
1) with distilled water shitosan being configured to concentration is 1~8% the aqueous solution, adds and the equiponderant gelatin class of shitosan again, stirs also heating, dissolves fully until solid phase;
2) the na-montmorillonite powder that weight is equivalent to solution weight 15~35% joins in the above-mentioned solution, stirs and makes suspension, then 30~60 ℃ of constant temperature 2~6 hours, and stirs frequently;
3) pressurization of above-mentioned suspension is sprayed in the cold solidification liquid, be stirred to it is solidified;
4) centrifugal or isolated by filtration, washing, sterilization, oven dry below 80 ℃, packing gets final product.
4. the preparation method of the blood-purifying adsorbing agent based on montmorillonite according to claim 3 is characterized in that said gelatin class is one or more in gelatin, agar and the agarose.
5. the preparation method of the blood-purifying adsorbing agent based on montmorillonite according to claim 3 is characterized in that said na-montmorillonite powder is natural na-montmorillonite powder.
6. the preparation method of the blood-purifying adsorbing agent based on montmorillonite according to claim 3 is characterized in that said na-montmorillonite powder is to make according to the following steps:
1) will be the sodium salt of montmorillonite 5~15% through separating the montmorillonite and the weight of purifying, and add water and stir, make the suspension ore pulp of concentration about 10%;
2) under 40~100 ℃ of temperature, ion-exchange reactions at least six hours, during stir frequently;
3) precipitation is removed the particle greater than 2 microns, and the upper strata suspension obtains na-montmorillonite behind centrifugal or filtering means dehydration, and water cleans for several times, and dehydration again;
4) gains are ground to less than 300 orders in oven dry below 80 ℃, obtain water content less than 10% na-montmorillonite powder.
7. the preparation method of the blood-purifying adsorbing agent based on montmorillonite according to claim 6 is characterized in that said sodium salt is a kind of in sodium chloride, sodium nitrate, the sodium sulphate or several.
8. the preparation method of the blood-purifying adsorbing agent based on montmorillonite according to claim 3 is characterized in that said solidification liquid is is 0.1~5% solution with one or more concentration that are configured in sodium phosphate trimer, sodium sulphate, sodium carbonate, natrium citricum and the NaOH.
9. the preparation method of the blood-purifying adsorbing agent based on montmorillonite according to claim 3 is characterized in that said sterilization is meant to be heated to 110~120 ℃ in steam, and kept 20~30 minutes.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031150179A CN1169612C (en) | 2003-01-20 | 2003-01-20 | Adsorbent based on montmorillonite for purifying blood and its preparing method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031150179A CN1169612C (en) | 2003-01-20 | 2003-01-20 | Adsorbent based on montmorillonite for purifying blood and its preparing method |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1431044A CN1431044A (en) | 2003-07-23 |
CN1169612C true CN1169612C (en) | 2004-10-06 |
Family
ID=4790557
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB031150179A Expired - Fee Related CN1169612C (en) | 2003-01-20 | 2003-01-20 | Adsorbent based on montmorillonite for purifying blood and its preparing method |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1169612C (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100393369C (en) * | 2006-09-20 | 2008-06-11 | 天津大学 | Gelatin, montmorillonite and chitosan multi-porous tissue engineering supporting material and preparation method thereof |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1314406C (en) * | 2003-04-17 | 2007-05-09 | 周良震 | Application of montmorillonite in pharmacy |
CN100434463C (en) * | 2006-09-08 | 2008-11-19 | 武汉大学 | Chitosan quaternary ammonium salt/organic montmorillonite nano composite material and preparation method thereof |
CN105214624B (en) * | 2015-11-02 | 2017-08-04 | 李建中 | A kind of dialyzate adsorption stuffing, its preparation method and application |
CN114904489A (en) * | 2022-05-31 | 2022-08-16 | 佛山市博新生物科技有限公司 | Blood perfusion adsorbent for removing uric acid and preparation method thereof |
CN117696017B (en) * | 2024-02-05 | 2024-05-07 | 四川大学华西医院 | Blood purification adsorption modified material and preparation method thereof |
-
2003
- 2003-01-20 CN CNB031150179A patent/CN1169612C/en not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100393369C (en) * | 2006-09-20 | 2008-06-11 | 天津大学 | Gelatin, montmorillonite and chitosan multi-porous tissue engineering supporting material and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
CN1431044A (en) | 2003-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103483487B (en) | Novel structure product, preparation method and use of styrenic resin | |
CA1241522A (en) | Ammonia scavenger | |
Goyal et al. | Nanostructured chitosan/molecular sieve-4A an emergent material for the synergistic adsorption of radioactive major pollutants cesium and strontium | |
CN105214624B (en) | A kind of dialyzate adsorption stuffing, its preparation method and application | |
RU2064429C1 (en) | Carbon sorbent and method for its production | |
US4460555A (en) | Ammonia scavenger | |
Colella | A critical reconsideration of biomedical and veterinary applications of natural zeolites | |
AU2017371552B2 (en) | Sorbent for a dialysis device and dialysis system | |
US7135156B2 (en) | Method for processing a zirconium oxide composition in crystalline form | |
CN1169612C (en) | Adsorbent based on montmorillonite for purifying blood and its preparing method | |
CN104667897B (en) | For adsorbing high endotoxic phenylethylene resin series in blood | |
CN112871139A (en) | Whole blood perfusion adsorbent, preparation method and application thereof | |
JPS6150008B2 (en) | ||
WO2020027922A1 (en) | Urease purification and purified urease products thereof, and sorbent cartridges, systems, and methods using the same | |
Singh et al. | Metal-organic frameworks for adsorption of fluoride for groundwater treatment | |
WO1984000885A1 (en) | Ammonia scavenger | |
KR20210094608A (en) | Methods and compositions for removing uremic | |
US9585913B2 (en) | Clay mineral for reducing inorganic phosphates, in particular in renal replacement therapy | |
CN1169611C (en) | Adsorbent based on hy drotalcite for purifying blood and its preparing method | |
CN115055157A (en) | Preparation and desorption method of zirconium modified zeolite-bentonite active particle dephosphorization filter material | |
CN100336829C (en) | Carboxymethyl starch sodium preparation, preparing process and use thereof | |
US11964266B2 (en) | Process for removing cobalt, lead, cadmium and chromium ions from bodily fluids using metallate ion exchange compositions | |
JPS58125607A (en) | Method of removing organic substance from phosphoric acid prepared by wet process | |
CN104667896B (en) | For removing the phenylethylene resin series adsorbent of high triglyceride in blood | |
CA3193778A1 (en) | Removing ions from bodily fluids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |